IFNA1 and melanoma: Vidutolimod (202), a virus like particle containing a TLR9 agonist known as G10, enhanced IFN-α production by pDCs showing high therapeutic efficacy when administered alone or in combination with an anti-PD-1 therapy in patients with melanoma (203, 204).